Collegium Pharmaceutical
COLL
244 hedge funds and large institutions have $1.3B invested in Collegium Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 84 increasing their positions, 87 reducing their positions, and 21 closing their positions.
1,158% more call options, than puts
Call options by funds: $478K | Put options by funds: $38K
100% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 21
44% more capital inflows, than outflows
Capital inflows: $159M | Capital outflows: $110M
9% more funds holding
Funds holding: 224 → 244 (+20)
4.07% more ownership
Funds ownership: 111.05% → 115.12% (+4.1%)
3% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$19.7M |
| 2 |
Janus Henderson Group
London,
|
+$15.3M |
| 3 |
Two Sigma Investments
New York
|
+$8.42M |
| 4 |
Walleye Capital
New York
|
+$7.97M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$7.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rubric Capital Management (New York)
New York
|
-$11.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$10.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$9.35M |
| 4 |
Eventide Asset Management
Boston,
Massachusetts
|
-$8.71M |
| 5 |
J. Goldman & Co
New York
|
-$7.2M |
COLL Hedge Fund Activity: Q3 2025 in Review
244 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2025, worth a combined $1.3B — up 23% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new COLL positions and 21 closed out — a net gain of 21 holders — while 84 added to existing stakes and 87 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $19.7M. The largest seller was Rubric Capital Management (New York), cutting an estimated $11.5M.
- 244 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2025, up from 224 in Q2 2025.
- Funds reported $1.3B of Collegium Pharmaceutical stock for Q3 2025, up 23% quarter-over-quarter.
- 42 funds opened new Collegium Pharmaceutical positions in Q3 2025 and 21 closed out, a net change of +21 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2025 was Goldman Sachs, an estimated $19.7M added.
- The largest Collegium Pharmaceutical seller in Q3 2025 was Rubric Capital Management (New York), an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2025.